• Shares in tech developer Datametrex AI (DM) are continuing to fall, despite the company releasing an improving third quarter report
  • Third quarter revenue leapt 186 per cent up to just over C$4.8 million, compared to last year’s corresponding period
  • Nevertheless, the company still posted a net loss of $451,353 due to $607,997 in option issuance expenses and $194,517 of depreciation and amortization expenses
  • With fears of extended pandemic-induced recession fading, the previous bullish sentiment surrounding the company’s COVID-19 test kits appears to have abated in recent weeks, sending Datametrex’s share price downward
  • Datametrex AI is currently down 16.67 per cent and is trading at 10 cents per share

Shares in tech developer Datametrex AI (DM) are continuing to fall, despite the company releasing an improving third quarter report.

Third quarter revenue leapt 186 per cent up to just over C$4.8 million, compared to last year’s corresponding period. Similarly, earnings before interest, taxes, depreciation, and amortization moved into the black at $362,059, versus negative $539,116 in 2019 same quarter.

Nevertheless, the company still posted a net loss of $451,353 due to $607,997 in option issuance expenses and $194,517 of depreciation and amortization expenses. The net loss is a 35 per cent improvement on last year’s loss, but this fact has still failed to slow the company’s months-long share price fall.

Datametrex’s market share has been descending since late August, following a share price spike earlier in the year. Bullish sentiment surrounding the company’s COVID-19 test kits triggered a share buy-up back in April, sending Datametrex’s share price from one cent to 19 cents in a matter of weeks.

However, with fears of extended pandemic-induced recession fading and test kit sales remaining tepid, the company’s recent market performance is continuing to suffer.

Datametrex CEO Marshall Gunter said the company achieved multiple key milestones during quarter, a significant increase in gross revenue and improvement in its cash position.

“This positive outcome was a direct result of our quick response in implementing a plan to begin selling test kits as result of the global impact of the COVID-19 virus. This resulted in a substantial improvement to the bottom line,” he added.

Datametrex AI is down 16.67 per cent and is trading at 10 cents per share at 11:34am EST.

More From The Market Online

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

From robotic limbs to new highs, NVIDIA stock is on a roll

NVIDIA Corp. (NDAQ:NVDA; NEO:NVDA) opens Tuesday trading on a positive note, showing a significant upward trend.

Hillcrest and Ocean Batteries deploy new energy storage systems

Hillcrest Energy Technologies (CSE:HEAT) completes its joint development agreement with Ocean Batteries to deliver its unique equipment.

ARway integrates tech with Apple’s new AI for Vision Pro

Arway.ai (CSE:ARWY) integrates Apple’s (NDAQ:AAPL) new enterprise APIs with its augmented reality solutions.